Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...
News-Medical.Net on MSN6d
Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetesSemaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...
Study underscores the direct vascular effects of this class of drugs, researchers say AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) ...
This between-group difference produced an estimated treatment ratio of 1.13 for semaglutide (95% CI 1.06-1.21), corresponding ...
Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Opens in a new tab or window CHICAGO -- Semaglutide further solidified ... to a median 26.4-meter improvement in maximum walking distance over placebo, reported Marc Bonaca, MD, MPH, of CPC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback